RNAZ White background cropped.jpg
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
05 nov. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
23 oct. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
RNAZ White background cropped.jpg
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
10 oct. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
10 sept. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
RNAZ White background cropped.jpg
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05 sept. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 août 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
RNAZ White background cropped.jpg
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
29 mai 2024 09h15 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
RNAZ White background cropped.jpg
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15 avr. 2024 09h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
RNAZ White background cropped.jpg
TransCode Therapeutics Reports 2023 Results; Provides Business Update
03 avr. 2024 09h10 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Reports 2023 Results; Provides Business Update